Retirement Planning Group LLC Buys 6,958 Shares of AbbVie Inc. $ABBV

by · The Cerbat Gem

Retirement Planning Group LLC raised its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 224.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 10,052 shares of the company’s stock after purchasing an additional 6,958 shares during the quarter. Retirement Planning Group LLC’s holdings in AbbVie were worth $2,327,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ABBV. Exencial Wealth Advisors LLC boosted its position in AbbVie by 3.5% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 41,311 shares of the company’s stock valued at $9,565,000 after buying an additional 1,405 shares during the period. Sage Private Wealth Group LLC grew its stake in shares of AbbVie by 45.9% in the third quarter. Sage Private Wealth Group LLC now owns 4,042 shares of the company’s stock worth $936,000 after purchasing an additional 1,272 shares during the last quarter. Family Capital Management Inc. grew its stake in shares of AbbVie by 13.5% in the third quarter. Family Capital Management Inc. now owns 3,094 shares of the company’s stock worth $716,000 after purchasing an additional 369 shares during the last quarter. Boothe Investment Group Inc. increased its holdings in AbbVie by 0.9% during the 3rd quarter. Boothe Investment Group Inc. now owns 29,463 shares of the company’s stock valued at $6,822,000 after purchasing an additional 264 shares during the period. Finally, Smith Shellnut Wilson LLC ADV raised its position in AbbVie by 18.7% during the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 4,427 shares of the company’s stock valued at $1,025,000 after purchasing an additional 698 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.2%

Shares of ABBV opened at $220.51 on Wednesday. The business’s 50 day moving average is $226.84 and its 200 day moving average is $216.04. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market capitalization of $389.72 billion, a PE ratio of 167.05, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

  • Positive Sentiment: AbbVie struck a three‑year voluntary agreement with the U.S. administration that exempts the company from tariffs and future pricing mandates while committing to major U.S. investment — a headline that reduces policy/regulatory uncertainty and signals long‑term U.S. capital deployment. Read More.
  • Positive Sentiment: AbbVie signed an exclusive global licensing deal (up to ~$5.6B) with RemeGen for RC148, a PD‑1/VEGF bispecific — this meaningfully expands AbbVie’s oncology pipeline and long‑term growth optionality. Read More.
  • Positive Sentiment: AbbVie is buying a drug‑delivery system and Arizona manufacturing facility from West Pharmaceutical and is investing in U.S. manufacturing (including a reported $175M plant spend) — supports supply chain control and the company’s U.S. investment pledge. Read More.
  • Neutral Sentiment: AbbVie joined peers in urging FDA updates to post‑approval change rules — could improve manufacturing flexibility but is a regulatory/industry‑wide request with uncertain timing. Read More.
  • Neutral Sentiment: A Phase 2 bipolar depression study (ABBV‑932) reached completion — a development milestone that requires readouts for directional impact. Read More.
  • Negative Sentiment: Under the U.S. deal AbbVie agreed to provide lower prices in Medicaid (and expand affordable offerings) — a meaningful concession that could weigh on near‑term revenue and margins for affected products. Read More.

Analyst Ratings Changes

A number of research firms have weighed in on ABBV. Piper Sandler reiterated an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Guggenheim lifted their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Morgan Stanley increased their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $246.89.

Read Our Latest Report on AbbVie

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).